NEW YORK, Jan 18, 2026, 05:13 EST — Market closed
- ImmunityBio shares ended Friday at $5.52, rising 39.8%, and climbed to $6.04 in after-hours trading.
- The company projected preliminary 2025 ANKTIVA net product revenue at around $113 million, marking an increase of about 700% compared to the previous year.
- New updates showed quicker trial enrollment in bladder cancer alongside early CAR-NK data revealing a 15-month complete response in Waldenström lymphoma.
ImmunityBio shares jumped sharply on Friday following a series of updates, including early sales figures for its approved bladder-cancer drug and new data from its development pipeline. The stock closed the day up 39.75% at $5.52 and later climbed to $6.04 in after-hours trading.
This move is significant as ImmunityBio aims to show it can convert a high-profile approval into steady revenue, while expanding the narrative beyond its flagship drug, ANKTIVA. Investors, meanwhile, have favored biotech stocks with upcoming catalysts and more defined commercialization strategies—both of which ImmunityBio delivered in a packed week.
Late Thursday, the company announced preliminary full-year 2025 net product revenue for ANKTIVA at roughly $113 million, marking a roughly 700% increase from last year. Fourth-quarter net product revenue came in around $38.3 million. Cash, cash equivalents, and marketable securities were estimated at $242.8 million by year-end. “We delivered strong quarter-over-quarter revenue growth,” CEO Richard Adcock said in the statement. Business Wire
ImmunityBio reported Friday that enrollment in its randomized QUILT-2.005 trial for BCG-naïve non-muscle-invasive bladder cancer is ahead of schedule, now over 85% complete. The company expects to wrap up enrollment by the second quarter of 2026. It plans to submit a biologics license application to the FDA by the end of that year.
The company also pointed to an interim analysis, requested earlier by the FDA, showing a longer duration of complete response—meaning no detectable cancer—with ANKTIVA plus BCG compared to BCG alone. BCG, or Bacillus Calmette-Guérin, remains the standard immune-based bladder treatment for early-stage disease.
ImmunityBio revealed follow-up data from its QUILT-106 trial, showing durable complete responses lasting up to 15 months in Waldenström lymphoma patients treated with an off-the-shelf CD19 CAR-NK therapy combined with rituximab. The company highlighted that, unlike many CAR-T treatments, patients received this therapy as outpatients without chemotherapy “lymphodepletion,” which typically clears immune cells before infusion. Business Wire
Regulatory momentum also picked up overseas this week. ImmunityBio announced that the Saudi Food and Drug Authority has granted accelerated approval for ANKTIVA, used with immune checkpoint inhibitors, to treat metastatic non-small cell lung cancer. The company highlighted this as its first approval for that indication and the first for subcutaneous administration.
The FDA has approved ANKTIVA for use alongside BCG in treating BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. Meanwhile, Merck’s Keytruda is cleared for certain high-risk patients with the same condition who either aren’t candidates for bladder removal surgery or choose to avoid it.
That said, the bull case shows clear signs of vulnerability. The recent CAR-NK update draws from just a few patients, and the revenue numbers remain preliminary and unaudited — conditions ripe for a swift shift if upcoming data or filings fall short of the market’s raised hopes.
U.S. markets were closed Monday for Martin Luther King Jr. Day, so ImmunityBio shares won’t see action until trading restarts Tuesday, Jan. 20.
As the session unfolds and the week progresses, traders will be focused on whether the stock can maintain its recent gains. They’ll also be watching for the company to back up its preliminary figures with full audited results, plus any extra details on 2026 sales momentum and regulatory timing.
